Libbs Farmacêutica and mAbxience, the biotechnology company of Chemo Group, signed in Brasilia a licensing and technology transfer agreement for several biosimilar monoclonal antibodies developed by mAbxience.
Libbs will invest US$ 100 million in the construction of a manufacturing site in Sao Paulo, expected to be ready by 2016, which will produce the biological compounds.
The agreement was signed in Brasilia by Hugo Sigman, Founder of Chemo Group, and Alvaro Athayde, vice-president of Operations and Management at Libbs. In attendance were Alexandre Padilha, Ministry of Health of Brazil, and Carlos Gadelha, Secretary of Science and Technology of Brazil.
mAbxience is a pioneer in the production of monoclonal antibodies in Latin America through its manufacturing facility pharmADN, located in Buenos Aires, Argentina, which started production last year. The biological products market in Brazil is the largest in the region, with sales of the main compounds reaching $ 1 billion.
“Our plant is the first of its kind in South America with capacity to produce monoclonal antibodies used in different types of cancer and autoimmune diseases. This agreement will enhance access to high quality medicines in the region,” said Dr. Hugo Sigman, Founder of Chemo Group.
“We believe that this is a very important milestone not only for our company, but also for Brazil, since we are opening the pathway of independence in Biotech, which until now was not accessible to the Brazilian industry,” said Alcibíades de Mendonça junior, Business VP of Libbs.
The new plant will operate under the name of Libbs Biotec, and will produce the end-to-end process of seven biosimilar products, from cell culture to fill & finishing. The deal terms include upfront and milestone payments, royalties and collaboration in clinical trials.
“mAbxience has commercial agreements signed in more than 30 countries,” said Carlos Bañado, Managing Director, mAbxience.
Source: Libbs, mAbxience press release